Partnership to accelerate the adoption of
next-generation sequencing (NGS) in clinical decision-making
Illumina, Inc. (NASDAQ: ILMN) and QIAGEN N.V. (NYSE: QGEN)
(Frankfurt Prime Standard: QIA) today announced a 15-year
partnership intended to broaden the availability and use of
NGS-based IVD kits, including companion diagnostics, for patient
management.
The agreement grants QIAGEN non-exclusive rights to develop and
globally commercialize IVD kits to be used together with Illumina’s
MiSeq™ Dx and NextSeq™ 550Dx Systems. The agreement also includes
rights for expansion of the partnership on future Illumina
diagnostic (Dx) systems. Both partners are also exploring
opportunities for QIAGEN to develop and market companion
diagnostics based on Illumina’s TruSight Oncology (TSO) assays that
enable comprehensive genomic profiling of tumor samples in
immunotherapy.
Illumina and QIAGEN will cooperate to commercialize a menu of
clinically validated workflows that combine QIAGEN’s proprietary
content and bioinformatics solutions. The partnership will
initially focus on commercializing oncology IVD kits to support
patient management and may expand in the future to include
additional clinical diagnostic fields, such as cardiology,
hereditary diseases, infectious diseases, as well as inflammatory
and autoimmune diseases.
“We are committed to expanding the range of clinical use cases
addressed by genomic sequencing by enabling partners to deliver IVD
tests and companion diagnostics on Illumina’s Dx instruments,” said
Francis deSouza, Chief Executive Officer of Illumina. “Our
partnership with QIAGEN will complement Illumina’s TSO 500 family
with additional testing menu options, accelerating NGS adoption in
oncology patient management.”
“Bringing together our highly complementary capabilities marks
an important milestone to advance the use of NGS technologies in
clinical decision-making and our shared vision of using this
powerful technology to improve the outcomes for patients
worldwide,” said Peer M. Schatz, Chief Executive Officer of QIAGEN.
“We at QIAGEN are very pleased with this ground-breaking
partnership and this first step in what we hope to be a long and
productive relationship that capitalizes on combining our unique
strengths. This partnership becomes a key cornerstone of our NGS
strategy, which continues to include our universal solutions for
use with any sequencer as well as the GeneReader NGS System for use
primarily with smaller, targeted gene panels. Through this
partnership, we look forward to creating significant benefits for
customers and for both parties, as well as to allowing QIAGEN to
maximize our opportunities as a company creating value by offering
sample-to-insight solutions.”
Bringing Together Highly Complementary Capabilities
Through this partnership, QIAGEN endeavors to build a broad menu
of IVD tests on Illumina’s Dx sequencers by leveraging its market
leading companion diagnostic capabilities and Sample to Insight
solutions, thereby enhancing both companies’ channel reach and
presence in the IVD market.
QIAGEN is an established global leader in molecular (PCR and
NGS-driven) precision medicine given its portfolio of more than 25
master collaboration agreements with pharmaceutical and
biotechnology companies to co-develop and gain regulatory approvals
for companion diagnostics. So far, seven therapies have received
FDA co-approval with a QIAGEN companion diagnostic assay.
With global availability of the MiSeq Dx and NextSeq 550Dx
platforms, Illumina has a robust diagnostic NGS product portfolio
capable of covering a broad range of clinical applications designed
for a variety of clinical lab settings. As NGS testing begins to
play a more significant role in patient care, Illumina is committed
to providing clinical solutions, both Illumina developed and
partner driven, that support the diagnosis and management of human
diseases.
About Illumina
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as the global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture and other emerging segments. To
learn more, visit www.illumina.com and follow @illumina.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading
global provider of Sample to Insight solutions that enable
customers to gain valuable molecular insights from samples
containing the building blocks of life. Our sample technologies
isolate and process DNA, RNA and proteins from blood, tissue and
other materials. Assay technologies make these biomolecules visible
and ready for analysis. Bioinformatics software and knowledge bases
interpret data to report relevant, actionable insights. Automation
solutions tie these together in seamless and cost-effective
workflows. QIAGEN provides solutions to more than 500,000 customers
around the world in Molecular Diagnostics (human healthcare) and
Life Sciences (academia, pharma R&D and industrial
applications, primarily forensics). As of June 30, 2019, QIAGEN
employed approximately 5,200 people in over 35 locations worldwide.
Further information can be found at http://www.qiagen.com.
Certain statements contained in this press release may be
considered forward-looking statements within the meaning of Section
27A of the U.S. Securities Act of 1933, as amended, and Section 21E
of the U.S. Securities Exchange Act of 1934, as amended. To the
extent that any of the statements contained herein relating to
QIAGEN's and ILLUMINA’s products, launches, regulatory submissions,
collaborations, markets, strategy, taxes or operating results,
including without limitation its expected net sales, net sales of
particular products, adjusted net sales, adjusted diluted earnings
per share results, product launches, improvements in operating and
financial leverage, currency movements, and plans for investment in
its portfolio and share repurchase commitments, are
forward-looking, such statements are based on current expectations
and assumptions that involve a number of uncertainties and risks.
Such uncertainties and risks include, but are not limited to, risks
associated with management of growth and international operations
(including the effects of currency fluctuations, regulatory
processes and dependence on logistics); variability of operating
results and allocations between customer classes; the commercial
development of markets for our products to customers in academia,
pharma, applied testing and molecular diagnostics; changing
relationships with customers, suppliers and strategic partners;
competition; rapid or unexpected changes in technologies;
fluctuations in demand for QIAGEN's and ILLUMINA’s products
(including fluctuations due to general economic conditions, the
level and timing of customers' funding, budgets and other factors);
ability to obtain regulatory approval of products; difficulties in
successfully adapting products to integrated solutions and
producing such products; the ability to identify and develop new
products and to differentiate and protect our products from
competitors' products; market acceptance of new products and the
integration of acquired technologies and businesses; and the other
factors discussed under the heading “Risk Factors” contained in
Item 3 of QIAGEN’s most recent Annual Report on Form 20-F and Item
1A of ILLUMINA’s most recent Quarterly Report on Form 10-Q and
Annual Report on Form 10-K. For further information, please refer
to the discussions in reports that each of QIAGEN and ILLUMINA has
filed with, or furnished to, the U.S. Securities and Exchange
Commission (SEC).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191007005792/en/
Illumina Contacts Jacquie Ross, CFA Vice President,
Investor Relations +1 858-882-2172 ir@illumina.com
Jen Carroll Associate Director, Public Relations +1 858-882-6822
pr@illumina.com
Karen Birmingham Head of Public Relations – Europe, Middle East
and Africa +44 7500 105665 kbirmingham@illumina.com
QIAGEN contacts John Gilardi Vice President Corporate
Communications and Investor Relations +49 2103 29 11711 and +1 240
686 2222 john.gilardi@qiagen.com
Phoebe Loh Associate Director Investor Relations +49 2103 29
11457 phoebe.loh@qiagen.com
Dr. Thomas Theuringer Head of External Communications +49 2103
29 11826 and +1 240 686 7425 thomas.theuringer@qiagen.com
www.twitter.com/qiagen www.facebook.com/QIAGEN
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Apr 2024 to May 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From May 2023 to May 2024